Researchers in Milan have uncovered a biological pathway that may explain why people with bipolar disorder struggle with memory and focus even when their mood is stable—a finding that could reshape how doctors treat the condition. A novel study published in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging is the first to identify how metabolic dysfunction directly links to changes in brain structure and cognitive symptoms in mood disorders, with particularly striking effects in bipolar disorder compared to major depressive disorder.
The distinction matters because these two conditions, though they share similar depressive symptoms, have different biological roots. Understanding those roots is urgent: mood disorders are among the most disabling psychiatric conditions, impairing not just emotional regulation but also the ability to concentrate and remember—the invisible taxes of mental illness that make everyday life exhausting even during periods of stability.
Elena Mazza, Ph.D., a psychiatrist and neuroscientist at IRCCS Ospedale San Raffaele in Milan, led the investigation into a relationship increasingly recognized in medicine: the tight link between mood disorders and metabolic problems. Obesity, diabetes, and insulin resistance all correlate with depression risk, and the reverse is also true. Mazza and her team wanted to understand whether this connection could explain the cognitive troubles that persist in bipolar disorder specifically. They studied 78 patients with major depressive disorder and 81 with bipolar disorder, measuring insulin resistance, related hormones, brain structure, and cognitive performance in memory, attention, and executive function.
What they discovered was striking in its specificity. Patients with bipolar disorder showed a more severe metabolic profile, characterized by both insulin resistance and leptin dysregulation—abnormalities in two hormones critical to how the body regulates energy and how the brain uses glucose. Crucially, greater illness burden—more mood episodes and manic episodes over a lifetime—correlated with worse metabolic dysfunction. But the key finding was this: metabolic alterations like insulin resistance were associated with cognitive deficits specifically in bipolar disorder, likely because these metabolic problems reduce gray matter volume in brain regions essential for memory, attention, and thinking.
The mechanism appears to work through inflammation and cellular damage. Insulin and leptin resistance promote inflammatory and neurotoxic processes that literally shrink the gray matter in regions supporting cognition. Remarkably, these associations were not observed in major depressive disorder, suggesting that metabolic pathways play a uniquely important role in bipolar disorder's cognitive symptoms. Cameron S. Carter, editor-in-chief of the journal and a physician at UC Irvine School of Medicine, notes that these findings align with a "neuroprogressive model" of bipolar disorder—the idea that repeated mood episodes may cause cumulative biological damage.
The implications are significant. Current treatments for bipolar disorder focus mainly on stabilizing mood, but this research suggests that targeting metabolic pathways could offer a new lever for improving cognition itself. For the millions of people managing bipolar disorder, this opens the possibility of interventions addressing not just emotional symptoms but the persistent fog that clouds memory and focus—the symptoms that often prevent people from working, studying, and engaging fully in their lives. Understanding this metabolic link moves toward more targeted, personalized approaches for a condition that remains highly heterogeneous and often delays diagnosis and effective treatment.